Skip to main content
PMC home page
Cancer Biology & Medicine logoLink to Cancer Biology & Medicine
. 2015 Sep;12(3):259. doi: 10.7497/j.issn.2095-3941.2015.0055

Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy

Cristina Teixidó 1, Niki Karachaliou 2, Maria González-Cao 2, Daniela Morales-Espinosa 2, Rafael Rosell 1,2,3
PMCID: PMC4607823  PMID: 26487971

In the published article1, one error appeared on page 89.

Pembrolizumab has not yet received FDA approval for NSCLC patients. In October 2014 pembrolizumab received FDA breakthrough therapy designation for lung cancer treatment supported by data from a phase Ib trial in previously treated NSCLC patients2.

The authors apologize for the errors and for any confusion it may have caused.

Acknowledgements

We are thankful to Dr. Dickran Kazandjian from FDA/Office of Hematology and Oncology Products for pointing out this mistake.

References

  • 1.Teixidó C, Karachaliou N, González-Cao M, Morales-Espinosa D, Rosell R. Assays for predicting and monitoring responses to lung cancer immunotherapy. Cancer Biol Med 2015;12:87-95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-2028. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Biology & Medicine are provided here courtesy of Chinese Anti-Cancer Association

RESOURCES